1-6 of 6
Patrice Herait, MD
Close
Sort by
Journal Articles

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

Catherine Thieblemont, MD PhD, Anastasios Stathis, MD, Giorgio Inghirami, MD, Lionel Karlin, Franck Morschhauser, MD PhD, Mary Gleeson, FRCPath, Florence Broussais, MD, Sandy Amorim, MD, Gilles Salles, MDPhD, Thierry Facon, MD, David Cunningham, FMedSci, Norbert Vey, MD PhD, Fabrice Bourdel, MSc, Patrice Herait, MD, Emanuele Zucca, MD
Journal: Blood
Blood (2014) 124 (21): 4417.
https://doi.org/10.1182/blood.V124.21.4417.4417
Published: 2014
Journal Articles

Bromodomain Inhibition By OTX015 Regulates c-MYC and HEXIM1 in a Panel of Human Acute Leukemia Cell Lines

Marie-Magdelaine Coudé, Thorsten Braun, Jeannig Berrou, Mélanie Dupont, Raphael Itzykson, Aline Masse, Emmanuel Raffoux, MD, Maria Eugenia Riveiro, Patrice Herait, MD, Andre Baruchel, MD, Hervé Dombret, MD PhD, Claude Gardin
Journal: Blood
Blood (2014) 124 (21): 5957.
https://doi.org/10.1182/blood.V124.21.5957.5957
Published: 2014
Journal Articles

Preclinical Evaluation of the BET-Bromodomain (BET-BRD) Inhibitor OTX015 in Leukemia Cell Lines Harboring the JAK2 V617F Mutation

Maria Eugenia Riveiro, PhD, Lucile Astorgues-Xerri, PhD, Charlotte Canet-jourdan, Mohamed Bekradda, MD, Esteban Cvitkovic, MD, Patrice Herait, MD, Eric Raymond, MD PhD
Journal: Blood
Blood (2014) 124 (21): 873.
https://doi.org/10.1182/blood.V124.21.873.873
Published: 2014
Journal Articles

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

Hervé Dombret, MD PhD, Claude Preudhomme, MD PhD, Céline Berthon, MD, Emmanuel Raffoux, MD, Xavier Thomas, MD PhD, Norbert Vey, MDPhD, Carlos Gomez-Roca, MD, Mark Ethell, MD, Karen Yee, MD, Fabrice Bourdel, MSc, Patrice Herait, MD PhD, Mauricette Michallet, MD PhD, Christian Recher, MDPhD, Christophe Roumier, Bruno Quesnel, MD
Journal: Blood
Blood (2014) 124 (21): 117.
https://doi.org/10.1182/blood.V124.21.117.117
Published: 2014
Journal Articles

Genetic Factors Predicting The Response To BET Bromodomain Inhibitors In Lymphoma Lead To New Synergistic Combinations

Eugenio Gaudio, PhD, Ivo Kwee, PhD, Andrea Rinaldi, PhD, Michela Boi, PhD, Elena Bernasconi, B.Sc., Monica Testoni, B.Sc., Anastasios Stathis, MD, Patrice Herait, MD, Kay Noel, PhD, Giorgio Inghirami, Emanuele Zucca, MD, Francesco Bertoni, MD
Journal: Blood
Blood (2013) 122 (21): 3070.
https://doi.org/10.1182/blood.V122.21.3070.3070
Published: 2013
Journal Articles

Preclinical Study Of The Bromodomain Inhibitor OTX015 In Acute Myeloid (AML) and Lymphoid (ALL) Leukemias

Thorsten Braun, MD, PhD, marie Magdelaine Coude, Pharm D, Jeannig Berrou, Sibyl Bertrand, Eugenia Riveiro, MD, PhD, Patrice Herait, MD, PhD, Andre Baruchel, MD, PhD, Hervé Dombret, Claude Gardin, MD
Journal: Blood
Blood (2013) 122 (21): 4218.
https://doi.org/10.1182/blood.V122.21.4218.4218
Published: 2013